| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1393069 | European Journal of Medicinal Chemistry | 2011 | 7 Pages |
Novel 4″-O-benzimidazolyl clarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activities. These benzimidazolyl derivatives exhibited excellent activity against erythromycin-susceptible strains better than the references, and some of them showed greatly improved activity against erythromycin-resistant strains. Compounds 16 and 17, which have the terminal 2-(4-methylphenyl)benzimidazolyl and 2-(2-methoxyphenyl)benzimidazolyl groups on the C-4″ bishydrazide side chains, were the most active against erythromycin-resistant Staphylococcus pneumoniae expressing the erm gene and the mef gene. In addition, compound 17 exhibited the highest activity against erythromycin-susceptible S. pneumoniae ATCC49619 and Staphylococcus aureus ATCC25923 as well. It is worth noting that the 4″-O-(2-aryl)benzimidazolyl derivatives show higher activity against erythromycin-susceptible and erythromycin-resistant strains than the 4″-O-(2-alkyl)benzimidazolyl derivatives.
Graphical abstractNovel 4″-O-benzimidazolyl clarithromycin derivatives were designed, synthesized and evaluated for their in vitro antibacterial activities. Compound 17 showed the highest activity against the erythromycin-susceptible and the erythromycin-resistant strains, much better than the references.Figure optionsDownload full-size imageDownload as PowerPoint slideHighlights►Novel 4″-O-benzimidazolyl clarithromycin derivatives were synthesized and evaluated. ►The derivatives showed excellent activity against erythromycin-susceptible strains. ►Some of them showed greatly improved activity against erythromycin-resistant strains. ►4″-O-(2-aryl)benzimidazolyl derivatives had higher activity than other derivatives. ►The other derivatives are the 4″-O-(2-alkyl)benzimidazolyl derivatives of CAM.
